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Abstract
Background: Parkinson's disease is caused by a dopamine deficiency state in the fore brain area.
Dopamine receptor agonists, MAO-B inhibitors, and N-Methyl-D-Aspartate (NMDA) receptor
antagonists are known to have antiparkinson effect. Levodopa, a dopamine structural analog, is the
best currently available medication for the treatment of Parkinsons disease. Unfortunately, it also
induces side effects upon long administration time. Thus, multidrug therapy is often used, in which
various adjuvants alleviate side effects of levodopa and enhance its antiparkinsonian action.
Results: Computer models have been created for three known antiparkinson mechanisms using
the MCASE methodology. New drugs for Parkinsons disease can be designed on the basis of these
models. We also speculate that the presence of biophores belonging to different groups can be
beneficial and designed some potential drugs along this line. The proposed compounds bear
pharmacophores of MAO-B inhibitors, dopamine agonists and NMDA antagonists, which could
synergistically enhance their antiparkinson effect.
Conclusions: The methodology could readily be expanded to other endpoints where drugs with
multiple activity mechanisms would be desirable.
Background
Parkinson's disease (PD) is the prevalent neurodegenera-
tive disorder of adults and is believed to be due to a
dopamine deficiency state in the fore brain area. It is
caused by the death of more then 75% of mid brain
dopamine producing neurons. Tremor, rigidity, and aki-
nesia characterize the disease. Genetic and environmental
factors are believed to initiate Parkinson disease. The en-
vironmental theory of PD recently received strong support
from the work of Greenamyre et al.[1].
At present there is no satisfactory medication for the treat-
ment of PD. Levodopa, which is a dopamine structural an-
alog is the "golden standard" in PD, but its side effects
upon long term administration (dyskinesia, dystonia, etc,
[2]) compel the search for drugs with better pharmacolog-
ical profiles. Other dopamine (DA) agonists do not pro-
vide adequate therapeutical response [3]. Thus, multidrug
therapy is usually often used. In this therapy various adju-
vants alleviate side effects of levodopa and enhance its an-
tiparkinsonian action. Three main groups of compounds
were found to have antiparkinson effect. These are
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dopamine (DA) receptor agonists, MAO-B inhibitors, and
N-Methyl-D-Aspartate (NMDA) receptor antagonists [4].
The monoamine oxidase enzyme exists under two forms,
MAO-A and MAO-B. Dopamine is oxidized in the brain
by the MAO-B form. MAO-B inhibitors maintain
dopamine concentration by blocking the MAO-B enzyme,
whose activity is also known to increase with age [5]. In
addition, MAO-B inhibitors can block the formation of
toxic metabolites from the compounds that are capable to
cause PD (e.g. MPTP [1]).
The beneficial action of DA agonists is based on direct
stimulation of the DA receptors. There are two classes of
dopamine receptors: D1 (D1, D5 subtypes) and D2 (D2,
D3, D4 subtypes). The antiparkinson action of dopamine
agonists was found to be mainly due to the stimulation of
the D2-class receptors [6]. Therefore we favored in the
present work those DA agonists that exhibit at least mod-
erate activity toward D2-class of DA receptors.
NMDA antagonists were observed to enhance the thera-
peutic effects of dopaminomimetics in PD. They block the
glutamatergic (excitatory) pathways that are overstimulat-
ed in PD [7]. Such action decreases the influx of calcium
ions into the neuron, and hence downregulates the activa-
tion of calcium dependent enzymes. This can prevent the
neuronal excitotoxic damage.
We set to identify the pharmacophores responsible for
each of these pharmacological activities so as to provide
guidelines for the synthesis of new and possibly more po-
tent analogues. We also speculated that better drugs could
be identified that contain more than one biophore, possi-
bly providing activity at multiple sites. We therefore de-
signed some potential drug by grouping several biophores
into a single molecule, thereby creating a single molecule
cocktail of drug activity.
The use of such a drug might reduce side effects stress im-
posed on the patients, while the synergy of its effects
might improve overall response.
Methods
Information about available MAO-B inhibitors [8–11],
DA agonists [12–15], and NMDA antagonists [16–19,38–
40] was collected from literature sources. Their structures
were coded and three separate databases (MAO inhibi-
tors, DA agonists, and NMDA antagonists) were created
and submitted to analysis by the MCASE program.
MCASE is a powerful analysis tool, whose principles have
been described in detail elsewhere [20]. Basically the pro-
gram works with databases of structurally diverse com-
pounds, where each entry contains the structural formula
of a molecule and its activity in a specific endpoint.
MCASE looks for key-features that may be responsible for
the observed activity of the compounds of the database.
The basic idea is that if a substructure is related to the ob-
served activity, it will be found mainly in active and mar-
ginally active compounds. On the other hand, if it is not
relevant to the observed activity, it will be randomly dis-
tributed amongst active and inactive compounds of the
database. The substructures that are seen to be responsible
for activity are called biophores[20], which in the case of
pharmacological process are basically the pharmacoph-
ores.
The compiled databases contain qualitative data about
compounds. Our MAO inhibitors database used data
from Kalgutkar [8] and others. It consists of compounds
tested as potential MAO inhibitors. Two strategies were
tried with this database. In the first approach, the selectiv-
ity of MAO-inhibitors was used as the main criterion ("Se-
lectivity database"). Hence, the preferable MAO-B
inhibitors were treated as "actives", while MAO-A inhibi-
tors where entered as "inactives", and unselective MAO in-
hibitors as compounds of "marginal activity". In the
second strategy, only the actual activity of inhibitors to-
wards MAO-B form was considered ("Activity database").
Under these conditions all compounds that inhibit the
MAO-B enzyme were treated as "active" and the others as
"inactive". More details will be given later during the dis-
cussion of the specific databases and their biophores.
For the DA database obtained from the paper by Seeman
[12] and others, agonists are listed as "active", while an-
tagonists are entered as "inactive". Partial agonists are
seen as compounds with "marginal activity".
The third database contains information about NMDA
antagonists and includes compounds collected from vari-
ous reports ([16,21] and others). The database was created
as follows: NMDA antagonists were set as "actives",
NMDA agonists as "inactives" and partial agonists as
"marginally actives".
In addition, to ensure that databases built on the bases of
selectivity also possess structural information about the
corresponding generic activities (binding to the NMDA or
DA receptors, inhibiting both MAO isoforms), active
compounds were required to have low Ki (the dissocia-
tion constant of the molecule-receptor (enzyme) com-
plex).
Models were created automatically by the MCASE pro-
gram for each of these databases. These models were test-
ed for robustness and reliability. In order to estimate the
quality of the models "ten-off validation procedures were
performed for each database. In these validation proce-
dures, ninety percents of all compounds from a databaseBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/8
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were selected randomly and used as learning set to create
a "reduced" model. The remaining ten percents of mole-
cules ("test set") were then tested against the reduced sets
to evaluated the predictive power of these models. Three
trials often-off validations were performed for each data-
base. The results are shown in Table 1.
As can be seen, good predictions, i.e. high concordance
and wide coverage (almost all chemicals from the test sets
received a prediction) were obtained for all databases. The
ability to recognize active compounds was slightly better
(by about 5%) for the DA database, whereas for the MAO-
B and the NMDA databases the situation was reversed. In
Table 1: Statistics of the MAO, DA and NMDA databases
DA database 249 molecules, 135 are active, 105 are inactive and 9 are marginal
Test Sets Sensitivity (%)a Specificity (%)b OCP (%)c Coverage (%)d
1 100.00 100.00 100.00 100.00
2 86.70 88.90 87.50 100.00
3 100.00 80.00 91.67 96.00
Average 95.57 89.63 93.06 98.67
NMDA database 374 molecules, 145 are active, 211 are inactive and 18 are marginal
Test Sets Sensitivity (%) Specificity (%) OCP (%) Coverage (%)
1 85.71 88.24 87.10 88.57
2 76.92 88.24 83.33 81.08
3 81.25 93.33 87.10 88.57
Average 81.30 89.93 85.84 86.07
MAO database Selectivity approach 239 molecules, 73 are active, 124 are inactive and 2 are marginal
Test Sets Sensitivity (%) Specificity (%) OCP (%) Coverage (%)
1 100.00 100.00 100.00 100.00
2 85.70 100.00 95.00 95.24
3 100.00 100.00 100.00 91.30
Average 95.23 100.00 98.33 95.51
MAO database Activity approach 237 molecules, 98 are active, 118 are inactive and 21 are marginal
Test Sets Sensitivity (%) Specificity (%) OCP (%) Coverage (%)
1 90.00 100.00 95.65 100.00
2 91.70 100.00 95.83 100.00
3 91.70 100.00 95.45 95.65
Average 91.13 100.00 95.64 98.55
a Ability to predict active compounds correctly b Ability to predict inactive compounds correctly c The percentage of Observed Corrected Predic-
tions (OCP) d Probability for an unknown compound to receive a statistically satisfactory prediction.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/8
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fact, we prefer to underpredict activity (i.e. some experi-
mentally active molecules being predicted to be inactive)
rather than overpredict it (when some experimentally in-
active molecules are predicted to be active), since overpre-
diction can lead to the design of drug candidates that lack
efficacy. Overall, high coverage and good predictive power
by all models indicated that the database's biophores are
not products of chance-correlation, but are relevant to the
specific activity types they represent.
As an additional validation, each model was tested with a
large group of structurally diverse molecules, which were
taken from the FDA rodent carcinogenicity database [35].
Results (Table 2) demonstrate good specificity of the
models. Number of predicted "active" compounds with
unaccounted activity is low (approximately 1% for the
NMDA and DA database and even less for the MAO-B da-
tabases).
The most reliable biophores from each model were then
selected as initial structural elements for the construction
of new drug prototypes.
Results
MAO-B inhibitors
IC50, the concentration of inhibitor that decreases enzyme
activity by 50%, does not provide sufficient mechanistic
information as it depends on the conditions of the exper-
iment [8]. Therefore it cannot be used to compare mecha-
nistically diverse data as in our case. Instead, we used Ki,
the dissociation constant of the enzyme-inhibitor com-
plex, to compare the activity of different inhibitors. In-
deed, this is a better indicator of a molecule's potential to
reversibly inhibit the enzyme. Furthermore reversible in-
hibitors are less likely to cause enzyme malfunction [8]
than irreversible ones.
As mentioned earlier the selective and reversible inhibi-
tion of MAO-B versus that of MAO-A is the major criterion
used to create the "Selectivity database" (Table 1). Chem-
icals with a   ratio greater than 10 were
considered to be selective MAO-B inhibitors and therefore
were used as "active" entries, while compounds with a ra-
tio less than 0.1 were considered to be selective MAO-A in-
hibitors and thus "inactive". MAO inhibitors which ratio
was within 0.1–10 range were considered as unselective
MAO-B inhibitors and were treated as "marginally active"
molecules.
In the "Activity database" (Table 1), inhibitors with a Ki
(MAO-B) value less than 1 µM were treated as "active",
while compounds with a Ki (MAO-B) value in the 1–5 µM
range were treated as "marginally active" molecules. All
those with a Ki (MAO-B) larger than 5 µM were entered as
"inactive".
• The best biophores (Table 3) to be used for the deriva-
tion of new and better drugs were selected from the MAO
datasets on the base of the following criteria:
• The biophore should have a high probability to be rele-
vant to activity (PRA). The lowest acceptable PRA value
was 75%.
A sufficient number of molecules should contain the se-
lected biophore. The biophore should be present in at
least 10 compounds.
Analysis of biophores #1, #2 (#4, #5) showed that both of
them occur in substituted 5-[4-(benzyloxy) phenyl]-1,3,4-
oxadiazol-2-(3H)-ones and their analogs (Figure 1),
many of which are known to be strong MAO-B inhibitors
[9]. Biophore #2 represents a flexible -CH2O- bridge be-
tween aryl moieties and was found to enhance the activity
and selectivity of the inhibitors as shown in the original
work [9]. Biophores #1 and #2 include aromatic moieties,
whose main function is presumably to bind to the hydro-
phobic site of MAO.
Table 2: Results of testing databases with generic drug-like moleculesa
Database DA NMDA MAO-B (Selectivity approach) MAO-B (Activity approach)
Test set size 1251 975 1251 1251
Predicted activeb 25 13 0 4
Proved activec 83 0 0
a FDA Rodent Carcinogenicity database [35] was the source of chemicals for the test sets b All compounds predicted to be "active" and with suffi-
cient confidence level of the prediction c Predicted "active" chemicals, which activity was reported in the literature
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Table 3: Some biophores of MAO, NMDA and DA databasesa
#b i o p h o r e s P R A b A\I\Mc #B i o p h o r e s P R A A \ I \ M
MAO (selectivity approach) MAO (activity approach)
1 100.0 44\0\0 4 99.90 30\0\0
2 99.37 12\0\1 5 100.0 51\0\5
3 99.98 12\0\0 6 99.99 13\0\1
NMDA
7 91.67 10\0\0 9 91.30 20\1\0
8 88.00 21\2\2 10 81.82 17\3\0
DA
11 100.0 82\2\5 14 93.75 18\0\0
12 99.98 54\3\6 15 100.0 22\1\0
13 93.75 14\1\0 16 93.75 9\1\0
a Thickened lines represent biophores, dashed lines reflects general structural backbone around the biophore, in which side chains can occur. Sites 
of common branching are shown with shortened bonds. b PRA – MCASE calculated probability (%) that the biophore is relevant to activity. c A\I\M 
– Number of Active, Inactive and Marginal compounds that contain this biophore
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Biophore #3 (#6) exists in N-(2-Aminoethyl)-benzamides
with substitutions on the aryl ring. These compounds are
known to be time-dependent inhibitors of MAO-B [22].
Several QSAR and CoMFA analyses were published, re-
porting relevant properties and structural parameters that
govern MAO inhibition [23–26]. All of them were per-
formed for narrow data sets and hence the results were
confined to the same group of compounds. We used these
studies to confirm the relevance of some of our biophores.
For example, biophore #2 was found to be an important
factor enhancing the interaction between the inhibitor
and the protein core of the MAO enzyme [23,25,27].
NMDA antagonists
The NMDA receptor consists of two subunits that together
create a membrane channel. Each subunit belongs to the
NR1 or NR2 subunit family. Various splice variants are
also known [16]. Activation of the NMDA channel re-
quires that glutamate and glycine bind at the same time to
NR2 and NR1 subunits respectively. Thus, three main
types of NMDA antagonists are known: glycine-site antag-
onists (binds to NR1 subunits), glutamate-site antagonists
(binds to NR2 subunits) and channel-blockers. In order to
avoid unwanted side effects, NMDA antagonists should
have either low affinity for the NMDA receptor (e.g. ami-
no-adamantane derivatives) or bind with high selectivity
to one type of NMDA receptor (e.g. ifenprodil, eliprodil,
or similar compounds) [16].
The chemicals used in the NMDA database were required
to have significant affinity for the NMDA receptor. For
that purpose, Ki (the dissociation constant of the mole-
cule-receptor complex) of accepted NMDA antagonists
was required to be less than 5 µM. The same criteria were
used in the selection of the best biophores from the
NMDA model as were described in the case of the MAO
databases (Biophores #7–10, Table 3).
Biophore #7 features the glutamate-binding site of NMDA
antagonists (Figure 2). The molecules that contain it are
derivatized amino acids, whose phosphonate group is a
functional replacement of the γ -carboxyl group of glutam-
ic acid. The phosphonate group of the NMDA antagonist
binds to the glutamate-receptor, as does the natural ago-
nist glutamic acid, but no conformational change that ac-
tivates the NMDA channel occurs [28]. Beart et al [21]
performed a SAR analysis of this type of NMDA antago-
nists. They report a deep hydrophobic pocket (good for
binding of the class of compounds shown in Figure 3B)
and a region to accommodate the ω -phosphonate-group
(biophore #7 binding site) [21] as structural-features of
the binding site of NMDA competitive antagonists. The
generic structure of these NMDA antagonists is shown in
Figure 2.
Figure 1
Location of biophores #1, #2 (A) and #4, #5 (B) in oxadia-
zolones and their analogs. Thickened lines represent bio-
phores. R - Cl, alkyl, or alkoxy group. X = O or S; Z = CN or
OH [9];
O
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Figure 2
Glutamate-site NMDA antagonists, which contain biophore
#7. There are generic structures such as (A), (where n - 1, 3;
R, R1 are H or alkyl) and subclasses with an aromatic moiety
such as in (B). Dashed line specifies backbone structure.
Most active conformations of dashed carbon chain are trans
for all bonds in the chain [21]
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Biophores #8 and #9 are characteristic of the NMDA chan-
nel blockers. Biophore #8 features an aromatic residue
that presumably binds to the hydrophobic pockets of the
channel walls (e.g. Triptophan-593, Alanine-627 [29]).
The nitrogen of biophore #9 can contribute to activity
possibly by interacting with the negatively charged resi-
dues or by forming hydrogen bonds (e.g. Asparagine-598
[29]).
Figure 3A) shows the generic structure of an NMDA antag-
onist that carries biophores #8 and #9 and B) the relative
locations of biophores #8, #9 and #10 in the eliprodil mo-
lecular family. Biophores #8, #9, and #10 also occur in the
NMDA antagonists that bind to glutamate-binding site of
NMDA receptor (e.g. #8 in SDZ EAB 515, #9 in SDZ EAA
494, #10 in SDZ 220-581, [21,37]).
Thus the NMDA biophores that were identified actually
characterize two groups of NMDA antagonists: channel
blockers and glutamate-site antagonists.
Dopamine agonists
The same strategy was used to create the Dopamine ago-
nists database as was used for the NMDA database. Com-
pounds with substantial affinity for dopamine receptors
(Ki within nanomolar range) were collected. The best bio-
phores were selected using the same criteria as those used
to assess the NMDA and the MAO databases (Table 3
#11–16).
Biophore #12 identifies the ortho hydroxyl groups of the
catechol ring, which is one of the structural features of
dopamine and its derivatives. Biophore #11 describes ag-
onists that possess only one hydroxyl, in meta-position
(preclamol, RU-24213, RU-24926, etc). This biophore
demonstrates the relative importance of the meta-hy-
droxyl group as compared to the para-hydroxyl group. For
example meta-tyramine's binding affinity to the
dopamine receptor is significantly greater than that of
para-tyramine [30].
Biophores #14 and #15 characterize DA agonists without
hydroxyl groups in the aromatic ring. Putatively, the aro-
matic nitrogen of this biophore carries the function of the
meta-hydroxyl group since it has the same structural loca-
tion relatively to the phenylethylamine backbone.
Most of the compounds that contain biophore #13 (9 out
of 12 active compounds) also carry a hydroxyl group (Ta-
ble 3). The majority of compounds that contain biophore
#16 also have at least one hydroxyl in one of the three
possible branching positions (Table 3). Metabolites of
such compounds might be more active than the parent
compound. Thus, aromatic hydroxylation of such com-
pounds at the ortho-position would form a catechol ring
(Table 3, #12) and produce metabolites that are structural
analogues to dopamine.
Both biophores #13 and #16 represent dopamine-like ag-
onists that have restricted conformation for the sake of en-
hanced binding.
Based on the biophores that were identified by the pro-
gram, a generic structure of the DA agonist was construct-
ed (Figure 4). The specifications for such structure include
a nitrogen atom separated by two carbon atoms from an
aromatic moiety and containing an electron donating
Figure 3
Generic structure of NMDA antagonists with biophores #8
and #9 (A). Where G is a hydrophobic group and R is Cl, F,
OH, or CH3. The shown compound (B) is illustrative of
eliprodil derivatives. Thickened lines represent biophores #8,
#9, and #10.
NG
N
Cl
OH
A
B
F
R
Figure 4
Generic structure of the dopamine agonist. Broken lines
imply possible branching, solid lines show the backbone
structure. EDG is an electron-donating group.
EDG NBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/8
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substituent at the meta-position. The importance of this
backbone finds support in a number of QSAR and CoMFA
analyses as well [30,31].
To ensure compatibility we compared biophores and bio-
phobes (fragments that are found to be responsible for
molecular inactivity) across all three databases and found
no collisions. On the contrary, structural overlap between
some biophores across the three databases was observed.
This was used as an additional encouragement to select
them for inclusion in prospective new drugs.
Discussion
The modeling procedure requires the construction of pre-
cursor candidates (precursor here is a molecule designed
to have a single mechanism of antiparkinsonian action)
on the basis of selected and compatible biophores of each
database. Precursor candidates for NMDA antagonism,
MAO-B inhibition and DA agonism were drawn to be
within the context of the types of molecules they are de-
rived from. The precursor structures that were generated
were then merged into candidate drug molecules.
Two types of precursors of active MAO-B inhibitors were
identified. The structure of the first one is shown in Figure
1 (1A and 1B) as a generic moiety. The second one is
based on a class of compounds that contain biophore #3,
whose structure is shown in Table 3 (Biophore #3). The
latter precursor has the advantage of small size and its ac-
tivity is quite tolerant to derivatization at the para-posi-
tion [22], whereas the former is known to have high oral
bioavailability and low toxic effects in rats [9].
A possible way of derivatization of the compound in Fig-
ure 1 (X = O, Z = CN, R = H) is substitution at the terminal
aromatic ring. Analysis of the original work [9] shows that
such substitution decreases binding affinity. However, the
decrease in activity is acceptable for methyl and methoxyl
substitutions in meta- and para-positions. Thus, the IC50
of the unsubstituted compound is 2.2 nM, whereas the
meta-methylated analog has an IC50 of 8 nM; the value for
the para-methylated is 15 nM, that of the para-methoxy-
lated is 27 nM, and the IC50 of the meta-methoxylated de-
rivative is 29 nM [9].
There are many possible choices for the selection of a suit-
able structure for an NMDA antagonist. One possibilitys
to use the backbone presented in Figure 3A; another one
is to use the generic structure of the glutamate-site NMDA
antagonists (Figure 2B). The latter group contains fewer
biophores, but there are some insights of its mechanism
of action and a structural analysis has been made for it
[21]. Hence, glutamate-site NMDA antagonists (Figure
2B) were favored as a structural prototype since some
NMDA antagonists from the former group (Figure 3A) ex-
press antagonistic activity toward dopamine receptors
(e.g. haloperidol).
Glutamate-site NMDA antagonists can be readily derivi-
tized. Thus the aryl ring (Figure 2B) can carry quite a large
variety of substituents that enhance binding if they are hy-
drophobic [21]. Since many good biophores were identi-
fied in the DA database we designed two different DA
precursors (Figure 5) instead of one. This was accom-
plished by combining a few biophores into a single mol-
ecule. Each of these precursors has structurally close
known homologues that are potent D2-type dopamine
agonists.
Figure 5
Proposed precursor molecules of DA database. Variant A
(homologue of TL 224) is a result of merging biophores #11,
#12, #15, and #16. Variant B (homologue of bromocriptine)
is based on biophores #11, #13, and #14.
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Figure 6
The best drug candidate compounds I and II, where X is O or
S; Y is H or Cl. DA, MAO and NMDA biophores are shown
with thickened lines.
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When merged together in different ways, the prototype
structures yielded a group of candidates. These com-
pounds were tested "in silico" against all compiled data-
bases (DA, MAO, and NMDA). Candidates with the best
predictions were submitted for further evaluation of their
pharmacokinetic parameters. Thus, they were tested
against databases predicting plasma protein binding affin-
ity [32], oral bioavailability and urine excretion (unpub-
lished results). The metabolism of each candidate was
then evaluated by the META program [33] using a mam-
mal metabolism database. LogP values (logarithm of the
n-octanol/water partition coefficient) were calculated by
the MCASE program on the base of a group contribution
approach [34].
Possible side effects of the drug candidates were assessed
by testing each candidate and its predicted metabolites
against carcinogenicity and mutagenicity databases [35],
[36].
Evaluating candidate molecules by the predicted pharma-
cokinetic parameters (Table 4) we favored those with
higher oral bioavailability scores and lower urine excre-
tion scores. For optimal sustained action, we chose a plas-
ma protein binding range of 50 to 90 percent.
The four finalists shown on Figures 6 and 7 received the
best overall prediction. Compounds III with X = O, Y = H
and OH in position 1, and compound II with X = S and Y
Table 4: Evaluation data for the best drug candidates (Figures 6 and 7)
Compound X Y OH LogPa PPB (%)b UE (%)a OB (%)c Warningse
I O H - 0.19 0.75 25.05 25.64 2.0
I S H - 0.72 0.75 25.05 25.64 1.0
II O H - 1.86 92.36 25.05 30.17 1.5
II O Cl - 2.53 93.25 25.05 30.17 1.0
II S H - 2.39 92.96 25.05 30.17 0.5
II S Cl - 3.05 93.79 25.05 30.17 0.5
III O Cl 2 0.96 89.75 45.48 4.56 0.0
III O Cl 1 0.96 89.75 45.48 22.24 0.5
III CH2 Cl 2 1.49 90.18 45.48 4.56 0.0
III CH2 Cl 1 1.49 90.18 45.48 10.3 0.5
III O H 2 0.3 88.32 16.64 4.56 0.0
III O H 1 0.3 88.83 16.64 22.24 1.0
III CH2 H 2 0.82 89.3 16.64 4.56 0.0
III CH2 H 1 0.82 89.3 16.64 10.3 1.0
IV O H 2 -1.37 86.64 45.48 7.03 0.0
IV O H 1 -1.37 87.24 45.48 22.24 1.0
IV CH2 H 2 -0.85 87.24 45.48 15.22 0.0
IV CH2 H 1 -0.85 87.8 45.48 10.97 1.0
a LogP calculated by MCASE b Predicted Plasma Proteins Binding (%), concentration of the compound in a bound form devided on its total concen-
tration in a blood c Predicted Urine Excretion (%), predicted amount of excreted drug relatively to its concentration in a blood d Predicted Oral 
Bioavailability (%). e Warnings reflect potential mutagenicity or carcinogenicity of compound. Compounds with warning level higher than 1.0 were 
considered possibly harmful.
Figure 7
The best drug candidate compounds III and IV, where X is 0
or CH2; Y is H or Cl. The second hydroxyl is in the position
1 or 2. DA, MAO and NMDA biophores are shown with
thickened lines.
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= H were selected as the most promising candidates since
their predicted oral bioavailability was among the highest
while the potential harmful side effects were predicted to
be low (Table 4). Nevertheless, the entire group of com-
pounds is proposed for synthesis and evaluation of their
potential antiparkinsonian activity. Structural variation
(changing X, Y, and the position of the hydroxyl group)
can be used for membrane permeability adjustment, en-
hancement of oral bioavailability and improvement of
Blood-Brain Barrier penetration.
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